Look Who’s Selling
LOOK WHO’S SELLING NTMD
The company’s chief medical officer exercised options to buy 60,000 shares last week at $1.16 and sold them for $21.94. In December, he sold 30,000 shares at $20.63 that he had acquired by exercising options at 8 cents a share. Meanwhile, the company itself has filed a ‘shelf registration’ to sell up to a quarter billion dollars worth of its stock and/or bonds – not an insignificant sum for a company this size.
Neither of these pieces of information is ‘dispositive,’ as they say – ‘finally determinative.’ But taken with the IMS prescription data suggesting that only a few hundred prescriptions for BiDil may have been written thus far (while expenses of more than $100 million for the year have been budgeted), one imagines that the chief medical officer, and the company, may be on to a good thing.
(A shelf registration doesn’t require a company to issue new securities, but puts it in a position to do so without regulatory delay.)
The stock closed last night at $19.90, for an overall market valuation, with just over 30 million shares outstanding, of $600 million.
Anything’s possible, but . . . don’t sell your puts.
BEFORE WE ATTACK IRAN . . .
The author argues that it’s a serious situation, but hardly a crisis.
Quote of the Day
A penny saved may be a penny earned, but it's one boring penny. A penny invested, on the other hand, bounces around. It gets bigger one day, smaller the next. A bit player in the drama of global finance, that penny buys a guy a balcony seat in the theater of macroeconomics.
~Susan StewartSearch
Request email delivery
Recent Posts
- Jan 22:
The Other Pillow Guy* - Jan 21:
How Great Was That? - Jan 20:
You Respond To Umair Haque - Jan 19:
The Three Big Lies - Jan 18:
Two Harvard Grads Still For Trump - Jan 15:
Of Insurrection, Inequality, And Your Stocks - Jan 14:
Meanwhile . . . - Jan 13:
Ronald Reagan Speaks - Jan 12:
What Do Adelson and Netanyahu Think? - Jan 10:
Post Trump, Post Truth
- Jan 22: